Back to Results
First PageMeta Content
Nitriles / Organofluorides / Prostate cancer / Ribbon symbolism / MDV3100 / Degarelix / Breast cancer / Erlotinib / Galeterone / Chemistry / Organic chemistry / Medicine


R&D Pipeline (October[removed]Global Development (1) Approval / Labeling Revision #Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.) Code No. Gen
Add to Reading List

Document Date: 2014-10-30 05:54:55

Open Document

File Size: 100,19 KB

Share Result on Facebook

Company

Medivation / NeurogesX / Injection UMN Pharma / Amgen / CK / Janssen Biotech Inc. / Kyowa Hakko Kirin / Ajinomoto / Seattle Genetics / AstraZeneca / Vical / Cytokinetics / Genentech / /

Continent

Asia / Europe / /

Country

Japan / United States / /

Event

Business Partnership / FDA Phase / /

Facility

D Pipeline / /

MedicalCondition

Non-Metastatic castration-resistant prostate cancer / non-metastatic biochemical recurrence US/Europe/Asia Phase-III Breast cancer US/Europe Phase-II / receptor antagonist Irritable bowel syndrome / nephropathy Oral In-house ASP3700 Osteoarthritis Oral In-house AGS67E Cancer / C receptor agonist ASP7373 Influenza / certolizumab pegol PEGylated anti-tumor necrosis factor-alpha antibody Disease / III Oral AstraZeneca New indication New formulation Hyperphosphatemia / Japan Bioequivalence study Oral GnRH antagonist Prostate cancer / disease / castration-resistant prostate cancer / urinary incontinence / roxadustat HIF stabilizer Anemia / Chronic / difficile infection / ASP9226 Neuropathic pain Oral In-house ASP3662 Alzheimer’s disease Oral In-house ASG-15ME Cancer / metastatic castration-resistant prostate cancer / Area / Phase ASP3652 Bladder pain syndrome / Oral In-house Infectious enteritis / pain / chronic kidney disease / Phase-l Target Disease Dosage Form Origin Cancer / sodium Prostacyclin receptor stimulator Chronic / Area / Phase Irritable bowel syndrome / diarrhea / Area / Phase Dosage Form Origin ASP7374 Influenza / renal failure / prostate cancer / hematopoietic cell transplant recipients US/Europe/Japan Phase-III Cytomegalovirus infection / idiopathic overactive bladder / ASG-22ME Cancer / ASP8273 Cancer Oral In-house ASP7962 Osteoarthritis / Area / Phase Dosage Form Origin Remarks Invasive aspergillosis / nephrosclerosis / /

MedicalTreatment

chemotherapy / organ transplant / dialysis / /

Organization

FDA / /

Product

H5N1 influenza Japan Phase-II Injection / Japan Phase-III Injection / US Phase-II Japan Phase-I Injection / Invasive candidiasis US Phase-III Injection / Europe Phase-II Dosage Form Origin Injection / nateglinide / Osteoporosis Japan Phase-III Injection / Hyperlipidemia Japan Phase-III Injection / Gastric cancer Japan Phase-III Injection / in / /

Technology

alpha / chemotherapy / ADC technology / dialysis / /

SocialTag